AKT1 and hepatocellular carcinoma: In HCC cells, NaHS treatment activates EGFR/ERK/MMP-2, PTEN/AKT, STAT-3/COX-2, and NF-кB and inhibits JNK signaling pathways (Figure 4) 126, 176, 177.